Type 2 diabetes continues to be on the rise globally, following like an angel of death in the wake of Third World famines and droughts. Therefore, it is no surprise that in 2018 there were 34.2 million Americans or more than 10% of the population with diabetes. What is surprising is that of those 34.2 million adults, 7.3 million of them went undiagnosed with a degenerative disease that requires early treatment, costing the US $327 billion in direct medical bills and reduced productivity. DIAGNOS (ADK.V), a Canadian developer of novel artificial intelligence solutions in the early diagnosis of diabetes, offers its FLAIRE artificial intelligence platform to enhance the capability of such applications as CARA or Computer Assisted Retina Analysis. The eyes have always been poetically associated with the soul, but they can be just as revealing about our physical health when it comes to diabetes. DIAGNOS’ AI-based CARA platform scans the back of your eye or retina for identifiable anomalies that signal the oncoming of diabetes. Spotting these anomalies early allows the physician to immediately begin treatment and quite likely avoid the signature blindness, heart disease and stroke so often attributed to diabetes. Putting DIAGNOS’ technology in the hands of the GP could potentially cut the line-up of patients waiting to see specialists by 65-70%. DIAGNOS, operating in 16 countries with 131 screening sites, is on the move, partnering with Saudi-based, Kanhoor Medical, for the last three years to deploy its AI medical retinal analysis through the Enayah Mobile Smart Eye Clinics in Saudi Arabia. Already the company has scanned thousands of participants in the humanitarian effort to combat blindness in a country with seven million diabetics. The company has also signed a three-year partnership agreement with CHUM in Montreal on AI projects related to various retinal diseases. With China turning into the world capital of diabetes, the global type 2 diabetes market is set to double to $58.7 billion by 2025. As such, DIAGNOS’ expert management, leading-edge IP and key governmental relationships could have their investors seeing stars.
